LungVax (autologous haptenized tumor cell vaccine) / AVAX Technologies - LARVOL DELTA

Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy. (PubMed, Nature) - "Here, using vaccines containing MHC class I (MHC-I) neoantigens (neoAgs) and different doses of tumour-derived MHC-II neoAgs, we discovered that whereas the inclusion of vaccines with low doses of MHC-II-restricted peptides (LDVax) promoted tumour rejection, vaccines containing high doses of the same MHC-II neoAgs (HDVax) inhibited rejection...We then documented modalities to overcome this inhibition, specifically via anti-LILRB4 blockade, using a CD8-directed IL-2 mutein, or targeted loss of cDC2/monocytes. Collectively, these data show that cytotoxic Tr1 cells, which maintain peripheral tolerance, also inhibit antitumour responses and thereby function to impede immune control of cancer."

Journal • Tumor-specific neoantigens • Oncology • CD4 • CD8 • CDK1 • GZMB • IL10 • IL2 • LILRB4 • PRF1

Scientists to develop vaccine to prevent lung cancer following £1.7m grant (PMLive) - "Scientists from University College London, the University of Oxford and the Francis Crick Institute are developing a vaccine to prevent lung cancer following a grant totalling up to £1.7m from Cancer Research UK and the CRIS Cancer Foundation. For the next two years, the team will receive funding to support lab research and the initial manufacturing of 3,000 doses of LungVax at the Oxford Clinical BioManufacturing Facility."

Financing • Non Small Cell Lung Cancer

High doses of MHC-II neoantigens in peptide cancer vaccines induce tumor-specific inhibitory cytolytic CD4+ T cells (SITC 2023) - "Results Vaccines containing tumor specific MHC-I neoAgs plus low doses of MHC-II neoAg (LDVax) promote tumor rejection...A similar reprogramming occurred following genetic depletion of cDC2 or treatment with a novel cis-targeted IL-2 mutein (CD8-IL2) that selectively activates CD8+ T cells. 2 Conclusions These results provide a roadmap to improve efficacy of cancer vaccines and potentially other immunotherapies by circumventing the generation/function of a heretofore unrecognized inhibitory CD4+ T cell population."

IO biomarker • Tumor-specific neoantigens • Oncology • Sarcoma • Solid Tumor • CD4 • CD8 • CDK1 • FOXP3 • GZMB • LILRB4

Increase in transforming growth factor-β didnot affect trombospondin1 in preeclampsia placentas. (PubMed, Turk J Obstet Gynecol) - "The SMAD2 mRNA relative expression (Livax) in the normal placenta was=0.71 (0.03-7.25); pre-eclampsia placenta (PE)=0.49 (0.01-40.71); p=0.075, the normal TSp-1 mRNA expression=1.08 (0.09-5.31); PE=0.21 (0.002-24.06); p=0.002...There was also no correlation between SMAD2 and TSp-1 mRNA in both normal and pre-eclampsia. TGF-β signaling in the preeclampsia placenta was changed due to the increased of the protein signaling it self without correlation between TGF-β to its receptors and TSp-1 relative expression."

Journal • Gynecology • SMAD2 • TGFB1 • TGFBR1 • TGFBR2 • THBS1